Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

4.400 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright ↗

September 22, 2026

Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB),...

Via MarketBeat

Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum ↗

September 22, 2026

Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during...

Via MarketBeat

Abeona (ABEO) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

ZEVASKYN revenue surged 31% to $11.4 million as treatment network expanded.

Via The Motley Fool

Topics Earnings

Abeona Therapeutics (NASDAQ:ABEO) Reports First Commercial Revenue and Bolstered Balance Sheet in 2025 ↗

March 17, 2026

Via Chartmill

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Abeona Therapeutics Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For...

Via Benzinga

Topics Earnings

Abeona Therapeutics Q2 Earnings Call Highlights ↗

August 13, 2026

Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that...

Via MarketBeat

Topics Earnings

Abeona (ABEO) Q1 2026 Earnings Transcript ↗

May 13, 2026

Abeona (ABEO) Q1 2026 Earnings Transcript

Via The Motley Fool

Abeona Therapeutics Q1 Earnings Call Highlights ↗

May 13, 2026

Abeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation...

Via MarketBeat

Topics Earnings

Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network ↗

May 13, 2026

Abeona Therapeutics Inc. (NASDAQ: ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.

Via Benzinga

Abeona (ABEO) Q4 2025 Earnings Call Transcript ↗

March 17, 2026

Abeona (ABEO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Keep an eye on the top gainers and losers in Wednesday's session. ↗

November 12, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 12, 2025

Via Benzinga

Here's Why Abeona Therapeutics Popped Higher Today ↗

November 12, 2025

This company is making excellent progress on its treatment for a very rare and serious skin disorder.

Via The Motley Fool

There are notable gap-ups and gap-downs in today's session. ↗

November 12, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Abeona Therapeutics (NASDAQ:ABEO) Stock Falls on Revenue Miss Despite Q3 EPS Beat ↗

November 12, 2025

Abeona Therapeutics beat Q3 EPS estimates but missed on revenue. The stock fell as investors focus on the delayed launch of its new gene therapy, ZEVASKYN.

Via Chartmill

What to Expect from Abeona Therapeutics's Earnings ↗

November 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 16, 2025

Via Benzinga

Abeona Posts Q2 Profit on Asset Sale ↗

August 14, 2025

Via The Motley Fool

Topics Intellectual Property

PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 27, 2025

Via Benzinga

Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗

May 27, 2025

Via Benzinga

Which stocks have an unusual volume on Thursday? ↗

May 01, 2025

Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.

Via Chartmill

Wednesday's session: top gainers and losers ↗

April 30, 2025

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease ↗

April 30, 2025

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

Via Benzinga

Abeona Stock Surges to 52-Week High: What's Behind The Move? ↗

April 30, 2025

Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene therapy.

Via Benzinga

Top stock movements in today's session. ↗

April 30, 2025

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 30, 2025

Via Benzinga

Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy ↗

April 29, 2025

FDA approves Zevaskyn as the first cell-based gene therapy for RDEB wounds after strong results in pivotal and long-term studies.

Via Benzinga

Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease ↗

April 29, 2025

ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, located across the U.S. with experience in cell and gene therapy.

Via Stocktwits

This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

March 05, 2025

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.